A Phase I Study of LY2584702 in Patient With Advanced or Metastatic Cancer.
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2014
At a glance
- Drugs LY 2584702 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Aug 2012 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 10 Jan 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 Jul 2011 New trial record